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the characteristics of community pharmacies in Egypt. The current study and 
future ones would significantly improve the ability to probe practice-related 
issues and economic challenges community pharmacies and pharmacists face in 
Egypt.  
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OBJECTIVES: HTA agencies are mushrooming in Europe. Industry faces the 
challenge to meet their diverse requirements and comply with decision criteria. 
Our aim was to investigate similarities and distinguishing characteristics of HTA 
agencies, to identify the anchor institutes that use different approaches to HTA 
and serve as a reference for others, and to assign other countries to one of the 
anchor institutes. METHODS: We identified the primary institutions in European 
countries where HTA plays a role in decision making. We developed a template 
for the unified assessment of the input needs of the agencies, and a set of 
criteria an anchor country should meet.. Agencies were assessed based on a 
literature review, and assigned to one of the anchor countries, which was 
validated by MSD subsidiaries across Europe. Future trends in anchor countries 
were investigated. RESULTS: We identified three anchor institutes in Europe 
using different value assessment concepts. IQWIG in Germany primarily 
assesses HTA submissions on the basis of patient related outcomes requiring 
hard endpoints. HAS in France sees the medical benefit of technologies in 
innovativeness rating them from no innovation to breakthrough innovation. 
NICE in England asks for evidence of cost-effectiveness as one of its major 
considerations. We found that other European countries tend to primarily follow 
one of these concepts. Analysing future trends, one can see converges in the 
fields of HTA requirements, between regulatory and HTA, in coordination and 
process harmonization, and regional and international collaboration. 
CONCLUSIONS: European HTA agencies can be systemized based on their 
requirements. This review can serve as a depository of individual country needs 
in HTA, an input to the design of clinical trials, and can support the development 
of industrial HTA strategies. Such a snapshot however cannot substitute the 
deep knowledge of local requirements and needs regular update to follow-up 
future trends.  
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OBJECTIVES: A pilot care managing programme was introduced in Hungary in 
1999. The conceptual foundations of the Hungarian implementation of managed 
care is closer to what was called the GP fundholding in the UK than HMOs in the 
USA. The purpose of the study is to analyse the changes in the number of 
enrolees in the care managing programme. METHODS: The data derive from the 
financial database of the Hungarian National Health Insurance Fund 
Administration (NHIFA) covering the period 1999-2007. We identified the average 
annual number of persons enrolled to Care Managing Organizations. The 
Hungarian CMOs was financed through a risk adjusted capitation fee and the 
health services covered by CMOs were defined in legal regulations. RESULTS: 
The total number of the Hungarian population was around 10 million people  
(100 %) during the study period. Since the beginning of the programme (1999) the 
total number of persons covered by the care managing programme increased 
from 158,984 (1.5 % of the Hungarian population) to 601,915 persons (5.9 %)  
in 2003 and to 1,961,025 (19.4 %) in 2005. After this peak, the number of enrolees 
decreased to 1,823,732 persons in 2006 and 1,409,475 persons in 2007. Later  
the Hungarian managed care pilot programme was cancelled. CONCLUSIONS: 
With the development of the Hungarian care managing system, the  
average number of enrolees increased. This increase resulted in larger risk-
pooling structure providing a more stable environment for Care Managing 
Organizations.  
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OBJECTIVES: To determine the types of approaches preferred by payers to 
enhance the P&T decision-making process and how medications accepted onto 
the formulary should be covered. METHODS: An online-interactive survey of US 
medical/pharmacy directors (MDs+PDs, respectively). In addition to a 10-point 
Likert scale (10=agree completely, 1=disagree completely), some questions used 
qualitative responses and interpretive analysis to explore views and beliefs. 
RESULTS: Twenty-nine (20 MDs+9 PDs) responded, representing 44 commercial 
plans,19 Medicaid plans, and 23 Medicare plans. Respondents indicated that 
current progress in obtaining usable comparative-effectiveness research (CER) 
information was slow (average=4.17; MD=4.06; PD=4.40 on the 10-point scale). 
However, they anticipate regularly utilizing CER information in formulary 
decision making by 2015 (average=6.03; MD=6.0, PD=6.1). Their rating of the use 
of evidence-based medicine in coverage decision making today was somewhat 
higher (average, 7.08; MD=7.38, PD=6.40). The survey participants pointed out 
that emerging CER results will greatly affect the following areas: 
Optimization/improvement of clinical guidelines (22.6%), medical/pharmacy 
benefit management (19.4%), evaluation of the value (16.1%), appropriateness of 
care (16.1%), pharmaceutical R&D (6.5%). When asked how they would change 
their plan/PBM’s pharmacy benefit design, the most frequent responses  
were incorporating CER data into copayment tiering management (13.3%), 
further incentivizing adherence through benefit design (10.0%), and altering 
benefit design structures for specialty pharmaceuticals (10.0%), primarily 
lowering member out-of-pocket costs. To improve their P&T Committee process, 
23.3% would incorporate more CER results, 13.3% would enhance the 
physician/specialist presence on the review committee, and 6.6% would increase 
the time allowed for review to allow for a more in-depth evaluation. 
CONCLUSIONS: The environment for P&T Committee decision making  
in managed care is undergoing a series of changes, and payer medical directors 
and pharmacy directors, who commonly serve as P&T Committee  
members, have distinct opinions as to how to alter the process to adapt to these 
influences.  
 
PHP145  
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OBJECTIVES: Patient Access Schemes (PASs) are part of the UK Pharmaceutical 
Price Regulation Scheme (2009). PASs enable patients to receive drugs, and allow 
pharmaceutical companies to collect cost-effectiveness and efficacy data, even if 
the payer classified the drug as outside the cost-effectiveness threshold. This 
project analysed the effect of PASs on patient access (PA) (defined by total sales 
in volume/prevalence of the particular disease group). METHODS: A literature 
search of Medline and online resources was carried out to capture relevant data 
on PASs, however no suitable publications on the relationship between PA and 
PASs were obtained. Multiple regression was used to test if a relationship exists 
between the dependent variable, (change in PA) and the independent variable 
(existence of a PAS) and other factors that may affect change in PA. The other 
factors were: type of PAS, country, number of competitors, list price, how long 
the drug has been marketed for, and the orphan drug designation. Five drugs 
with approved PASs in the UK were analysed. These included: lenalidomide, 
erlotinib, bortezomib, sunitinib, and cetuximab. These were analysed in France, 
Germany, Italy, Spain and the UK, between 2010 and 2011 using IMS sales data 
and the Globocan Project 2008 prevalence data. RESULTS: The results of the 
regression analysis showed the existence of a PAS does not seem to have an 
effect on the change in PA. Therefore, this model cannot support a relationship 
between these two variables. The R2 is 0.6119, however the only variable which 
was statistically different from 0 is the number of competitors, with a p-value of 
0.014; which means it is the only variable which had a significant effect on the 
change in PA. CONCLUSIONS: Further research needs to be conducted for a 
detailed analysis on this relationship.  
 
PHP146  
THE CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE FOR NEW 
TECHNOLOGIES, 1999-2012: MORE PREVENTION, DIAGNOSIS, AND COVERAGE 
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OBJECTIVES: The Centers for Medicare and Medicaid Services (CMS) makes 10-12 
National Coverage Determinations (NCDs) for medical interventions each year. 
Our objective was to identify evolving trends in NCDs. METHODS: We analyzed 
data from the Tufts Medical Center NCD database, which contains detailed 
information on 165 NCDs since 1999. We evaluated trends in how CMS reported 
evidence limitations, the use of its “coverage with evidence development” (CED) 
policy, the type of intervention evaluated, and whether it was for prevention or 
treatment. We used two-sided Armitage-Cochrane (CA) tests to identify 
statistical annual trends. RESULTS: Over time, CMS has increasingly cited 
evidence limitations in decision memoranda. The proportion of occasions CMS 
cited a “lack of relevant health outcomes” increased from 14% in 2000 to 67% in 2012 
(p<0.0001; CA test, 1999-2012). The proportion of occasions CMS cited, a “lack of 
studies including Medicare beneficiaries” increased from 7% in 2000 to 67% in 2012 
(p=0.0003; 1999-2012). CMS has increasingly relied on coverage with evidence 
development (CED) policies (p=0.0292; 2003-2012). Since 2009, 10 NCDs (29% of 
NCDs in this period) resulted in CED policies, more than half of all CEDs (n=19) 
implemented since 2003. In recent years, NCDs have increasingly pertained to 
primary and secondary prevention level interventions (p=0.0971; 1999-2012), and 
now represent 28% (46/165) of all NCDs. The type of intervention evaluated also 
changed, with more NCDs pertaining to “diagnostic imaging technology” 
(p=0.0971; 1999-2012), now representing 15% (25/165) of all NCDs, and “health 
education and behavior” (p=0.0195; 1999-2012), now representing 7% (11/165) of 
all NCDs. CONCLUSIONS: CMS’s NCD process is evolving in important ways. CMS 
increasingly notes that technologies considered lack relevant outcomes. The 
agency increasingly uses CED policies to grant narrow access to medical 
technology, while collecting evidence for future use. It increasingly uses NCDs to 
evaluate preventive services and diagnostic technologies.  
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OBJECTIVES: As payers decision makers increasingly become primary gate-
keepers for access to novel therapies, pharmaceutical, biotech and medical 
device manufacturers strive to fulfill the evidentiary requests of the pharmacy 
benefit managers and plan medical directors. This study attempts to gather 
information to inform manufacturers on the need and rationale behind the 
payers’ requests of head-to-head controlled studies. METHODS: We interviewed 
11 medical directors (MD) and 2 pharmacy directors (PD) of commercial health 
insurance plans; 4 pharmacy benefit managers (PBM); and 2 MD of Medicaid 
programs. The interviews focused on understanding product coverage decision 
making and formulary placement. The interviewers followed a discussion guide, 
but encouraged deeper conversation when appropriate. The interviews were 
carried out in the summer of 2012 and beginning of 2013. RESULTS: Seven out of 
13 (54%) medical directors spontaneously mentioned the need for direct 
comparison data in clinical trials to ensure adequate decision making. 
Conversely, only one PD out of the PBMs and PDs even mentioned comparison 
data and that was in the context of trying to understand the clinical trial design. 
Two MDs went on to further to state that if the head-to-head data showed 
increased efficacy that a price premium would be appropriate. Another MD 
stated that the head-to-head data may assist in formulary placement decisions. 
CONCLUSIONS: Payers will continue to demand head-to-head studies as long as 
these studies are seen as the mechanism to address their questions. By fostering 
a richer dialogue with payers to explore other mechanisms for gathering the 
comparative data, manufacturers may be able to satisfy the payers’ needs with 
less risky and more relevant study designs.  
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OBJECTIVES: Industrialized countries are increasingly adopting pay-for-
performance (P4P) mechanisms for quality improvement. The purpose of this 
work is to present a decision program that is able to estimate the cost-
effectiveness, budget impact, and health benefits of P4P programs. METHODS: 
The decision program builds upon previously published decision models on the 
cost-effectiveness of implementation programs. The model analyzes the three 
possible benchmarks for rewarding performance - absolute performance, 
improved performance, and relative performance. RESULTS: The model shows 
that when P4P programs do not lead to a substitution of other health care 
programs their incremental cost-effectiveness ratio (ICER) is deterministically 
determined and ranges from treatment ICER to infinity. This holds regardless of 
the reward mechanism. In case of a budget constraint a P4P program will be 
adopted only if it substitutes other programs with lower financial incentive to 
providers. Budget impact and health benefits are calculated as the difference in 
costs and health benefits between the P4P program and the programs that are 
replaced. A P4P program is cost saving when the programs to be substituted have 
higher per patient costs despite a lower financial incentive. CONCLUSIONS: The 
proposed decision program is able to deterministically model the cost-
effectiveness and budget impact of P4P programs under different reward 
mechanism and in the presence or absence of a budget constraint.  
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Patient financial contributions or copayments are an important funding source 
for access to medicine in both developed and emerging markets. In the former, 
they are on the rise as fiscally strapped health systems shift costs to patients; in 
the latter, they are declining as governments expand public funding for access. 
In this paper, we address three topics. First, we characterize the systems of 
patient contributions in eleven established markets and eight emerging markets 
using data from IMS and international organizations such as OECD. We also 
quantify the current level of use and the trends in application of patient 
contributions. Second, we conduct a systematic review of research literature on 
the impact of patient contributions published between 2000 and 2012 to examine 
if they achieve their intended policy objectives in practice. Specifically, we look 
at the implications of patient contributions on whether they (1) encourage 
responsible or rational medicine use by patients; (2) allow governments to 
contain public health care costs while still sustaining patient access to 
treatments; (3) provide flexible choice for patients who want to pay for non-
essential or premium treatments; and (4) increase overall patient access to 
medicine by increasing funding for health care allowing public investment to 
focus on higher need patients, or if they tend to displace public investments 
thereby increasing inequity of health care provision. We find that in some cases, 
patient contributions have the desired effects, while in other cases they have 
limited or even opposite effects. Whether or not patient contributions achieved 
desired objectives depends on the design of the policy, e.g., if these contributions 
discriminated between treatment choices or not. Third, based on our findings, 
we draw out key elements that patient contribution systems must have to 
achieve their objectives in developed and emerging markets.  
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In many countries policy makers are concerned about an increase in drug 
expenditures. One particular concern is the group of patented drugs. The 
purpose of this work is to present a proportional rule for setting ceiling prices of 
new innovative drugs. In essence, a proportional rule sets out that drug prices 
should only increase in proportion to incremental effectiveness. The rule of 
proportionality has its theoretical foundation in economic consumer theory, 
which states that willingness to pay (for drugs) is a direct measure of the 
marginal value (of beneficiaries) and thus changes proportional to marginal 
value. By measuring health benefits on a cardinal value scale it is ensured that 
prices change in proportion to the size of health benefits, in accordance with 
economic consumer theory. The suggested proportional rule combines four 
desirable features: first, it contains the growth of health expenditures without 
the need to eliminate currently funded programs; second, it enables a rapid 
assessment of cost-effectiveness without the need to calculate downstream 
costs; third, its calculation method is transparent and easy to understand which 
helps pharmaceutical companies in making better predictions about whether 
their investment in R&D is worth it; and forth, it obviates the need to put an 
explicit dollar value on a person’s life. Optionally, the decision rule can account 
for additional aspects beyond an increase in health benefits: i) lack of growth of 
gross domestic product; ii) price difference between patented drugs and generic 
drugs; and iii) savings which go beyond the reduction in clinical events.  
In summary, the suggested proportional rule avoids many of the shortcomings  
of existing cost-per-QALY rules while limiting the introduction of new 
weaknesses.  
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Among the many definitions of economics are several that focus on the role that 
prices and income play in determining human behavior. In many 
pharmacoeconomic studies little attention is paid to different levels of prices 
and the resulting differences in behavior. More important, in most studies based 
on randomized controlled trials there is no variation in price to examine and 
variations in income are not even measured. It is not so much that the authors 
believe that prices and incomes have no effect on behavior. It is more that the 
effect is believed to be minor or the goal of the study is not really an economic 
one. This paper will review the impact of changing prices and income on the 
behavior of patients, providers, payers, and pharmaceutical companies. The 
discussion of patient behavior will focus on the value of patient time and the role 
of out-of-pocket costs in determining adherence. Physician and hospital 
behavior will be considered in light of market prices of their inputs and outputs. 
Government and private payer behavior will be characterized. A brief discussion 
of pharmaceutical company profit incentives will be included. Finally, we will 
review the information typically used to get on a formulary in the United States. 
We propose adding discussion of behavioral responses to changing market 
conditions in pharmacoeconomic submissions to regulatory bodies including 
those making formulary decisions.  
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The medicines used for common ailments are stored by many household  
for emergency use. Many times these medicines expire despite being stored 
under prescribed conditions. It is important to dispose these medicines that are 
date expired and unused in an appropriate manner. The guidelines for disposal 
for medicines are prescribed by World Health Organization (WHO) and United 
States Food and Drugs Administration (USFDA). Some of the methods suggested 
to dispose date expired and unused medicines include returning to 
manufacturer, landfill, and waste immobilization: encapsulation/ inertization, 
flushing it down the Sewer and incineration. Despite precautions associated  
with these methods, these methods are not effective. Studies have shown that 
these methods sometime poses a risk not only to human beings by increasing 
chances of taking wrong medications, accidental poisoning, adverse drug 
reactions, drug-drug interactions that increases health burden but also to  
the environment. In India, the knowledge regarding disposal of date expired  
and unused medicines is lacking among common people. A conceptual 
framework to dispose date expired and unused medicine is devised. Pharmacies 
interested in program would be identified wherein patients visiting  
these pharmacies would be asked to register with pharmacy and return  
the unused/date expired medicines to participating pharmacies. The unused  
and date expired medicines collected in pharmacies shall be segregated into 
various types by participating volunteers. The segregation would include various 
dosage forms and packing material. The recovered contents will be sent to a 
specialist company that uses specific procedures in order to recycle the collect 
reusable components and safely dispose of chemical components based on 
prescribed procedures. The reusable components shall be collected and property 
treated for reuse. This concept would not only sensitize people but also 
community pharmacists and would be advantageous to protection of 
environment.  
 
